Oct, 13 2016 18:15 JST

Source: Eisai

Eisai to Officially Launch "Chocola BB Rich Ceramide" in Stores Nationwide

Japan's First Food with Function Claims Drink Containing Ceramide
- "Drink" to Counter Dry Skin -

TOKYO, Oct, 13 2016 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch its first food with function claims Chocola BB Rich Ceramide (Notification number: B60) in drugstores, pharmacies and convenience stores throughout Japan on Monday, October 17. The product is Japan's first drink that is a type of food with function claims containing glucosylceramide derived from rice.(1)

Ceramide is a component of the stratum corneum of the epidermis layer of human skin. Normally, ceramide fills the spaces between cells in the corneum of the skin, and plays a role in restraining the loss of moisture to the outside as well as protecting the skin from external stimuli such as ultraviolet rays. Therefore, a lack of ceramide advances transpiration of skin moisture, potentially leading to dryness in the skin. Since ceramide levels decline with age, it is important to appropriate replenish ceramide to counter dryness.

Containing glucosylceramide as its active component to make it harder for moisture to escape from the skin,(2) Chocola BB Rich Ceramide is a product that you can drink to counter dry skin. Furthermore, in addition to ceramide, the drink also contains collagen and hyaluronic acid which are known for their beauty properties, and is recommended for people who are highly beauty conscious. Chocola BB Rich Ceramide has a delicious, easy to drink pear flavor, is low in calories (8.2 kcal), and with zero caffeine, can be safely consumed before sleep.

Chocola BB Rich Ceramide is now available nationwide through a wide range of retail outlets including drug stores, pharmacies, convenience stores and Eisai's internet retailing site.

Centered around the signature OTC product Chocola BB Plus (Third-class OTC drug) for the relief of skin trouble, acne and mouth ulcers, Eisai has been expanding the Chocola BB brand to suit the needs and lifestyles of its customers such as Chocola BB Royal 2 (quasi-drug), a nutritional drink for invigoration when physically fatigued, Chocola BB Joma, a soft drink that contains vitamin B6 (Food with Nutrient Function Claims), and Chocola BB Mouth Ulcer Repair Shot (Third-class OTC drug), an oral care spray launched in August.

Through the Chocola BB brand, Eisai will continue to respond to the diverse needs of female consumers and support an ever-growing number of people to achieve health and beauty in their everyday lives.

(1) Chocola BB Rich Ceramide was accepted by the Consumer Affairs Agency as Japan's first food with functional claims drink that contains glucosylceramide derived from rice.

(2) For information such as the scientific basis of Chocola BB Rich Ceramide, please refer to the Consumer Affairs Agency's home page:
https://www.fld.caa.go.jp/caaks/cssc02/?recordSeq=41604270150104 (in Japanese only)


About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)
February 21 2018 08:25 JST
 
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
February 16 2018 07:34 JST
 
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
February 12 2018 09:03 JST
 
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan
February 01 2018 16:20 JST
 
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib)
January 22 2018 09:51 JST
 
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan
January 20 2018 18:32 JST
 
Eisai: Oral Antifungal Agent NAILIN Capsules 100mg Approved in Japan
January 19 2018 13:35 JST
 
Eisai Enters into Licensing Agreement with Adlai Nortye for Potential Anticancer Agent E7046
January 19 2018 13:23 JST
 
Eisai: Patent Infringement Litigation for Antiemetic Agent ALOXI in the United States
January 18 2018 09:30 JST
 
Eisai Completes Construction of Oral Solid Dose Production Facility at New Suzhou Plant in China
January 11 2018 10:46 JST
 
More Press release >>

Latest Press Release


More Latest Release >>